7-[2S-[3R-Hydroxy-(4-phenyl)-butyl]-5-oxo-pyrrolidin-1-yl]-heptanoic acid | 66598-64-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7-[2S-[3R-Hydroxy-(4-phenyl)-butyl]-5-oxo-pyrrolidin-1-yl]-heptanoic acid
• 英文别名: 7-[(2S)-2-[(3R)-3-hydroxy-4-phenylbutyl]-5-oxopyrrolidin-1-yl]heptanoic acid
• CAS: 66598-64-9
• 化学式: C₂₁H₃₁NO₄
• 分子量: 361.481
• InChiKey: WMEUGWYECRHASZ-RBUKOAKNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  26
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• EP4 receptor selective agonists in the treatment of osteoporosis
  申请人：——

  公开号：US20010047105A1

  公开（公告）日：2001-11-29

  This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists. This invention is especially directed to those methods wherein the EP4 receptor selective agonist is a compound of Formula I: 1 wherein the variables are as defined in the specification.

  这项发明涉及治疗低骨密度等病症的方法，特别是骨质疏松症、脆弱、骨折、骨缺陷、儿童特发性骨质流失、牙槽骨流失、下颌骨流失、骨折、骨切术、与牙周炎相关的骨流失或假体生长的方法，包括给予EP4受体选择性前列腺素激动剂。这项发明特别涉及EP4受体选择性激动剂为Formula I中的化合物的方法：1其中变量如规范中所定义。
• Method for treating ocular hypertension
  申请人：——

  公开号：US20040254230A1

  公开（公告）日：2004-12-16

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions that are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

  本发明涉及到前列腺素E2受体EP4亚型的有效选择性激动剂，以及它们的使用或制剂在治疗青光眼和其他与患者眼内压升高有关的疾病中。本发明还涉及使用这些化合物为哺乳动物（尤其是人类）的眼提供神经保护作用。
• 8-Azaprostaglandin analogs as agents for lowering intraocular pressure
  申请人：——

  公开号：US20030220506A1

  公开（公告）日：2003-11-27

  The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1 wherein X, Y, Z, D and R 3 are as defined in the specification.

  本发明提供了一种治疗眼压过高或青光眼的方法，该方法包括向患有眼压过高或青光眼的动物施用治疗有效量的通式 I 所代表的化合物； 1 其中 X、Y、Z、D 和 R 3 如说明书中所定义。
• METHOD FOR TREATING OCULAR HYPERTENSION
  申请人：Merck & Co., Inc.

  公开号：EP1461026A2

  公开（公告）日：2004-09-29
• 8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE
  申请人：Allergan, Inc.

  公开号：EP1503984A1

  公开（公告）日：2005-02-09